Startup Evvy raises $40M to accelerate precision diagnostics and medicine for women’s health

Evvy has closed a $40 million Series B round to expand its precision diagnostics and care platform for women’s health. Catalio Capital Management led the deal, with the U.S. Fertility Innovation Fund, Rethink Impact, Muse Capital and Alumni Ventures among the new investors. Existing backers, including LabCorp Venture Fund, General Catalyst and Left Lane Capital, also came back in.

The company, officially Allora Health Inc., is building around a blunt thesis: women’s medicine has been undermeasured for too long. Priyanka Jain, Evvy’s co-founder and CEO, says female biology has been overlooked in research, leaving women stuck with high rates of misdiagnosis for some conditions and repeat vaginal symptoms that keep coming back. She points to a long-running research gap, arguing that women were largely excluded from clinical trials of new drugs until 1993, which left only about 30 years of data focused on female biology.

Evvy says it has spent more than five years assembling what Jain calls the world’s largest clinical-grade dataset on the vaginal microbiome and women’s health outcomes. Its at-home kit uses metagenomic sequencing. Patients swab, the data goes into a machine learning system called EvvyAI, and the system turns that into a personalized prescription treatment plan that gets sharper as more tests come in.

The company says licensed clinicians using EvvyAI have diagnosed more than 90% of symptomatic patients and cut recurrence of conditions like bacterial vaginosis by 50%. Evvy says it has also identified six distinct BV subtypes, after finding that patients who looked similar under traditional criteria often had different microbiomes, recurrence patterns and treatment responses.

The new money is going toward validation of a new generation of AI-enabled diagnostic and care models for a wider set of women’s health conditions. Fertility is first on the list. Evvy says that area is especially complex because the vaginal microbiome is only one part of the picture, and it plans to share more findings later this year. So far, the company says its technology has reached more than 100,000 patients through 3,000 medical practitioners, and its dataset has been cited in 13 peer-reviewed publications.